Baudax Bio, Inc.
BXRXQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1,269 | $1,080 | $493 | $0 |
| % Growth | 17.5% | 119.1% | – | – |
| Cost of Goods Sold | $7,009 | $2,445 | $1,732 | $0 |
| Gross Profit | -$5,740 | -$1,365 | -$1,239 | $0 |
| % Margin | -452.3% | -126.4% | -251.3% | – |
| R&D Expenses | $3,887 | $3,125 | $9,087 | $20,061 |
| G&A Expenses | $0 | $0 | $0 | $27,012 |
| SG&A Expenses | $24,119 | $45,310 | $43,335 | $27,012 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $23,067 | -$30,794 | $21,125 | -$14,554 |
| Operating Expenses | $51,073 | $17,641 | $73,547 | $32,519 |
| Operating Income | -$56,813 | -$19,006 | -$74,786 | -$32,519 |
| % Margin | -4,477% | -1,759.8% | -15,169.6% | – |
| Other Income/Exp. Net | -$1,982 | -$763 | -$1,314 | -$38 |
| Pre-Tax Income | -$58,795 | -$19,769 | -$76,100 | -$32,557 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$58,795 | -$19,769 | -$76,100 | -$32,557 |
| % Margin | -4,633.2% | -1,830.5% | -15,436.1% | – |
| EPS | -177.3 | -361.16 | -5,714.8 | -4,872.07 |
| % Growth | 50.9% | 93.7% | -17.3% | – |
| EPS Diluted | -177.3 | -361.16 | -5,714.8 | -4,872.07 |
| Weighted Avg Shares Out | 332 | 55 | 13 | 7 |
| Weighted Avg Shares Out Dil | 332 | 55 | 13 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $2,303 | $1,359 | $0 |
| Depreciation & Amortization | $2,162 | $2,816 | $2,554 | $480 |
| EBITDA | -$33,581 | -$49,560 | -$72,187 | -$32,077 |
| % Margin | -2,646.3% | -4,588.9% | -14,642.4% | – |